AZN Trading Analysis - 10/22/2026 02:48 PM — TRU-SENTIMENT

News Headlines & Context

The following items are based on general knowledge and are separated from the data-driven analysis below:

• AstraZeneca (AZN) recently advanced late-stage oncology pipeline assets, with positive trial readouts supporting growth outlook in cancer therapeutics.
• The company announced expansion of manufacturing capacity in the US and Europe, aimed at meeting rising demand for biologics.
• Regulatory updates from the FDA on key drug approvals are anticipated in the coming quarter, representing a potential catalyst.
• Broader pharmaceutical sector has seen defensive inflows amid macro uncertainty, supporting large-cap names like AZN.
• Context: These fundamental catalysts align with the bullish options flow and upward price action observed in the embedded data, though no earnings date is specified in the provided datasets.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for AZN:

• Trailing P/E is 25.10 with trailing EPS of 6.74; forward P/E, PEG ratio, and price-to-book are null (not available).
• Market capitalization is 269.68B with 1.55B shares outstanding and institutional ownership at 64.71%.
• Dividend yield is 1.26% with a rate of 2.13 and ex-dividend date of 2026-08-07.
• Beta is 0.01 (extremely low sensitivity to market moves per data), historical volatility is 25.45%.
• 52-week range: low 153.41, high 212.71; current price near lower-mid of range.
• Revenue growth, profit margins, ROE, debt-to-equity, and free cash flow are null in data — cannot be assessed.
• Analyst consensus and target mean price are null; no sell-side target context provided.
• Fundamentals show stable earnings and low beta, diverging from strongly bullish technical and sentiment reads which imply near-term directional conviction not explained by fundamental fields.

Current Market Position

Minute bars show AZN traded from open 168.91 on 2026-10-21 09:30 to last close 173.89 on 2026-10-22 14:20, with intraday high 173.91 and low 173.32 in final bars. Daily history shows close on 2026-10-21 at 168.72, then minute data indicates continuation to ~173.89. Recent daily action: 2026-10-15 close 167.21 on volume 3.62M, then pullback to 164.24 by 2026-10-19, recovery to 168.99 on 2026-20, and 168.72 on 2026-10-21.

Intraday momentum is positive: five final minute bars show consecutive higher closes (173.32 → 173.89).

Technical Analysis

Price is above SMA 5 (166.85), SMA 20 (162.15), and SMA 50 (162.57) — bullish alignment, no bearish crossover. RSI 68.26 indicates strong momentum near overbought (70 threshold). MACD histogram positive (0.20) confirms bullish momentum. Bollinger Bands: price 168.72 is above upper band 170.43? Actually 168.72 is below upper 170.43 but above middle; near upper envelope. 30-day range: price at 168.72 is near high (169.84), about 94% up the range.

True Sentiment Analysis (Delta 40-60 Options)

Options flow via True Sentiment (Delta 40-60 only):

Call Volume: $1,070,860 (88.5%) Put Volume: $138,540 (11.5%) Total: $1,209,400

Sentiment is Bullish. Call contracts 1,119 vs put 64; call trades 18 vs put 10. Pure directional positioning shows strong conviction to upside. No divergence from technicals — both agree bullish.

Key Price Levels (Observational Only)